Tag: anti-tumor necrosis factor

Three JAK Inhibitors Get Boxed Warnings, Modified Indications

The arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR) poses an increased risk of serious cardiac events such as heart attack or stroke, cancer,...

Should IBD Biologics Be Offered in Combination or as Monotherapy?

Adding or switching biologics is a common practice in the treatment of patients with inflammatory bowel disease (IBD), but there is a dearth of clinical...

FDA Approves Ozanimod (Zeposia) for Ulcerative Colitis

The US Food and Drug Administration (FDA) has approved ozanimod (Zeposia) for adults with moderately to severely active ulcerative colitis (UC), the company has announced....

New Oral Protein Shows Promise for Ulcerative Colitis

A plant-based fusion protein is safe and effective for inducing favorable immune modulation in patients with mild to moderate ulcerative colitis with no immune suppression–side...

Tofacitinib Retreatment Effective for Ulcerative Colitis

Retreatment with tofacitinib after a period of treatment interruption was well tolerated and effective in patients with ulcerative colitis who had shown a previous response...

Worse COVID-19 Outcomes in IBD Patients Taking Corticosteroids

NEW YORK (Reuters Health) – Corticosteroids appear to worsen COVID-19 outcomes in patients with inflammatory bowel disease (IBD), but TNF antagonists do not, according to...